After 19 years of prescribing the standard protocol, one patient's refusal led a board-certified urologist to a compound that's been protecting Japanese men for generations — and that the American prostate industry was never designed to offer.
I've been a board-certified urologist for 19 years. I've personally treated over 9,200 men for prostate-related conditions.
I know what a healthy prostate looks like. I know the signs, the symptoms. And I know the permanent, painful end result of what an unhealthy one causes.
But over the last decade, something has been happening in my exam room that keeps me up at night.
Men are getting worse, not better.
Not because they aren't trying. But because every prostate medication I've been told to prescribe, and every supplement my colleagues recommend, was built on the same limited set of approaches — approaches that either mask the symptom or address the growth through systemic enzyme suppression.
I want to tell you about the Wednesday morning that changed how I practice medicine.
It was 8:45 AM on a Wednesday in September 2023.
James sat in my exam room for what was supposed to be a routine checkup. He was 64. Retired electrician. Married 38 years. Three grown kids, five grandkids.
I'd been treating James for nearly four years. Watched him decline visit by visit. First the nighttime trips — one, then two, then four. Then the daytime urgency. Then the mapping of bathrooms at his granddaughter's soccer games. Then the cancellation of his and his wife's annual fishing trip.
But that morning was different.
He was sitting on the exam table with his hands folded in his lap.
"Dr. Hartwell, I've tried like 6 different supplements," he said.
"My wife's been sleeping in the guest room for the last 16 months. But the worst part is she doesn't even say anything about it anymore."
I gave it to him straight.
I explained what DHT is — the potent androgen that drives prostate tissue growth — and why nothing on the supplement shelf meaningfully addresses it.
Two NIH-funded trials tested saw palmetto directly. The STEP trial (2006, NEJM) found it no better than placebo at the standard dose. The CAMUS trial (2011, JAMA) tripled the dose to 960mg/day — still no better than placebo on symptoms, flow rate, or prostate size.
The compound is a weak 5-alpha reductase inhibitor. At supplement doses, it cannot suppress DHT production enough to slow prostate tissue growth.
So I wrote him a script for finasteride. The standard next step.
He looked at it. Then he looked back at me.
"I don't know about this. I've watched too many of my friends take this stuff and lose their sex lives. I'm not doing it."
I tried to explain the data. He didn't budge. He left without filling it.
I told him to come back in 90 days and get checked.
I expected him to be miserable when he walked back in.
I was not prepared for what he said instead.
I left Dr. Hartwell's office angry that Wednesday. Not at him. He did what every urologist does. The prescription was the standard playbook.
I was angry at myself.
I'd just been buying every bottle that seemed like it had good reviews and solid ingredients, taking them for 30 days, then letting them collect dust in my bathroom cabinet.
I'd never once stopped to actually research what was causing the problem.
So that night I sat down at my kitchen table with a yellow legal pad and started reading the actual research. Not Reddit. Not WebMD. The clinical studies.
One in particular stopped me cold.
Epidemiological data consistently shows Japanese men over 60 experience prostate enlargement at significantly lower rates than American men of the same age. The difference has been documented across decades of published research.
The compound responsible is equol — a polyphenolic metabolite produced from soy isoflavones by specific gut bacteria. Approximately 60–70% of Japanese men produce it naturally. Only 20–30% of Western men do.
If DHT was the trigger, and finasteride worked but cost you everything else that made you a man — there had to be something in between. Something that addressed DHT without suppressing the enzyme that produces it.
That's exactly what equol does.
S-Equol — the active form — binds directly to DHT molecules and prevents them from activating the androgen receptor in prostate tissue. It doesn't inhibit 5-alpha reductase. It doesn't change how much DHT your body produces.
Finasteride changes production. S-Equol doesn't.
One is an enzyme inhibitor. The other isn't.
And there was a second pathway most people miss entirely.
SHBG — sex hormone-binding globulin — docks onto prostate cell membranes and triggers swelling through a mechanism completely separate from DHT. Standardized stinging nettle root occupies those binding sites before the protein can dock.
Two pathways. Two points of interference. Neither one involving enzyme suppression.
I found one product that combined both at the doses used in the published research: Saika — Prostate Intercept.
I ordered it that night.
Week 1: Honestly, didn't feel a difference.
Week 2–3: My stream got a little stronger. I stood at the toilet and emptied my bladder in one steady flow instead of three broken trickles.
Week 3–6: I slept from 11 PM to 4:30 AM without getting up. First time in over two years. I laid there confused for ten minutes before I realized what had happened.
Month 2: I felt like I had my life back. Sleeping through the night. My wife and I drove 3 hours to see our grandkids. I didn't pull over once.
After, she looked at me and said, "You used to have to stop halfway. What's different?"
I hadn't told her I started Saika. She just noticed.
3 months went by and James came back to my office.
I was expecting him to be miserable. Most men in this situation are now ready to negotiate taking finasteride.
But he walked into the exam room with a kind of energy that was unrecognizable from before.
I asked him how the symptoms were progressing.
He said, "I'm sleeping through the night and my stream's normal. Honestly feel like myself again."
I looked at him over my glasses. "Are you on the finasteride?"
He said no.
He told me he'd been taking a product with a compound called equol — and a second compound, stinging nettle root.
I ran his workup and told him, "Let me check everything before you leave."
The results came back about 40 minutes later while he was still in the office.
After 19 years treating men for prostate-related conditions, I had never seen improvement like this without pharmaceutical or surgical intervention.
His IPSS score had improved significantly. Uroflow was stronger. Post-void residual was down. All objective measurements had moved in the right direction — on a compound I'd never once put in front of a patient.
I went back into the exam room and told James the results.
Then I asked him a question I don't think I've ever asked a patient before.
"Can you write down the name of the supplement for me? I want to look into it."
He smiled. Wrote "Saika Prostate Intercept" on the back of one of my appointment cards. Slid it across the desk.
I kept that card.
That night I went home and started reviewing the published research on equol and stinging nettle root.
What I found was that Saika's formula was built on dual-mechanism research — not a single ingredient, but two distinct pathways working together.
S-Equol binds DHT molecules and prevents them from activating the androgen receptor in prostate tissue. It doesn't inhibit 5-alpha reductase. It doesn't change how much DHT the body produces. Finasteride changes production. S-Equol doesn't. That's a mechanistic difference a patient can verify with his own doctor.
Stinging nettle root addresses SHBG docking on the prostate membrane — a second pathway that operates independently of the DHT–androgen receptor axis.
Two points of interference. Neither one involving enzyme suppression. Clinical dosing. Third-party tested. No proprietary blend.
S-Equol binds DHT with high affinity, preventing it from activating the androgen receptor. It does not inhibit 5-alpha reductase and does not reduce systemic DHT production. This represents a mechanistically distinct approach from finasteride.
Stinging nettle root lignans bind SHBG with high affinity, blocking it from docking on prostate cell membranes and triggering swelling through a separate pathway.
I started recommending Saika cautiously. Patients who'd already refused prescriptions, or who'd been on saw palmetto for years with no improvement, or who came in with their wives, both clearly exhausted from the sleep disruption.
And within six weeks, almost every man came back saying some version of the same thing:
S-Equol paired with standardized stinging nettle root. Two compounds addressing two distinct pathways — DHT interception at the receptor and SHBG blockade at the membrane — without relying on 5-alpha reductase inhibition.
Dosed at the levels used in the published research. Third-party tested. No proprietary blend. No saw palmetto. No beta-sitosterol. No version of the mechanism two NIH trials proved insufficient.
Manufactured in an FDA-registered, GMP-certified facility in the US. Third-party tested.
Any customer who takes Saika for the full 60 days and does not feel a real difference gets a full refund. No shipping the bottles back. No forms to fill out. No conditions.
For many men with an enlarging prostate, the growth runs in one direction. Every year DHT continues to drive tissue growth is another year the gland has to enlarge, the obstruction has to tighten, and the bladder has to strain harder.
Once bladder muscle dysfunction reaches an advanced stage, full recovery isn't guaranteed.
Get a baseline IPSS score from your doctor. Start Saika. Run it for 8 to 12 weeks. Score yourself again.
Let your own numbers decide.